Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

被引：89

作者：

Allen, LF

Lenehan, PF

Eiseman, IA

Elliott, WL

Fry, DW

机构：

[1] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Clin Dev, Ann Arbor, MI 48105 USA

[2] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Oncol, Ann Arbor, MI 48105 USA

[3] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Canc Pharmacol, Ann Arbor, MI 48105 USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 03期

关键词：

D O I：

10.1053/sonc.2002.34049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：11 / 21

页数：11

共 115 条

[1] GROWTH-FACTORS AND CANCER [J].

AARONSON, SA .

SCIENCE, 1991, 254 (5035) :1146-1153

[2]

ALIMANDI M, 1995, ONCOGENE, V10, P1813

[3]

BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13

[4] Cyclin D1 in breast cancer [J].

Barnes, DM ;

Gillett, CE .

BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :1-15

[5]

Baselga J, 1999, SEMIN ONCOL, V26, P78

[6]

Baselga J, 1998, CANCER RES, V58, P2825

[7]

Bodey B, 1997, ANTICANCER RES, V17, P1319

[8] c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells [J].

Brandt, BH ;

Roetger, A ;

Dittmar, T ;

Nikolai, G ;

Seeling, M ;

Merschjann, A ;

Nofer, JR ;

Dehmer-Möller, G ;

Junker, R ;

Assmann, G ;

Zaenker, KS .

FASEB JOURNAL, 1999, 13 (14) :1939-1949

[9]

Bucci B, 1997, ANTICANCER RES, V17, P769

[10] A NEU ACQUAINTANCE FOR ERBB3 AND ERBB4 - A ROLE FOR RECEPTOR HETERODIMERIZATION IN GROWTH SIGNALING [J].

CARRAWAY, KL ;

CANTLEY, LC .

CELL, 1994, 78 (01) :5-8

← 1 2 3 4 5 6 7 8 9 10 →